NMRA trades 1126.8% below Wall Street's consensus target of $4.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NMRA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 19, 2026, Neumora Therapeutics, Inc. Common Stock (NMRA) has a Wall Street consensus price target of $4.50, based on estimates from 9 covering analysts. With the stock currently trading at $0.37, this represents a potential upside of +1126.8%. The company has a market capitalization of $68M.
Analyst price targets range from a low of $4.00 to a high of $5.00, representing a 22% spread in expectations. The median target of $4.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, NMRA trades at a trailing P/E of -0.4x. Analysts expect EPS to grow +12.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ACADACADIA Pharmaceuticals Inc. | $3.1B | $17.83 | $30.05 | +68.5% | Buy | 28.6x | 37 |
INVAInnoviva, Inc. | $1.4B | $18.40 | $38.00 | +106.5% | Buy | 7.6x | 11 |
AXSMAxsome Therapeutics, Inc. | $6.9B | $134.00 | $279.25 | +108.4% | Buy | — | 27 |
PRAXPraxis Precision Medicines, Inc. | $8.5B | $305.19 | $611.69 | +100.4% | Buy | — | 18 |
PTCTPTC Therapeutics, Inc. | $5.0B | $60.23 | $102.89 | +70.8% | Buy | 114.5x | 26 |
NRXPNRx Pharmaceuticals, Inc. | $48M | $2.80 | — | — | — | — | — |
ALTOAlto Ingredients, Inc. | $258M | $3.33 | $10.00 | +200.8% | Buy | 8.8x | 2 |
DFTXDefinium Therapeutics, Inc. | $3.9B | $29.12 | $20.00 | -31.3% | Buy | — | 1 |
LLYEli Lilly and Company | $1.3T | $1382.54 | $1445.12 | +4.5% | Buy | 39.1x | 46 |
PFEPfizer Inc. | $159.9B | $28.06 | $31.13 | +10.9% | Hold | 9.3x | 40 |
Quick answers to the most common questions about buying NMRA stock.
The consensus Wall Street price target for NMRA is $4.5, representing 1126.8% upside from the current price of $0.3668. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NMRA has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $4.5 implies 1126.8% upside from current levels.
NMRA's current price is $0.3668 with a consensus target of $4.5 (1126.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5 for NMRA, while the most conservative target is $4. The consensus of $4.5 represents the median expectation. These targets typically reflect 12-month expectations.
NMRA is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NMRA stock forecast based on 9 Wall Street analysts shows a consensus price target of $4.5, with estimates ranging from $4 (bear case) to $5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on NMRA, with a "Buy" consensus rating and $4.5 price target (1126.8% upside). 6 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NMRA analyst price targets range from $4 to $5, a 22% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.